Feasibility and Safety of Systemic rAAV9-hNAGLU Delivery for Treating MPS IIIB: Toxicology, Bio-distribution and Immunological Assessments in Primates
Human Gene Therapy Clinical Development · 2014
DOI: 10.1089/hum.2013.208 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy Clinical Development, 2014. Verfasst von Darren A Murrey und 14 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Murrey, D. A., Naughton, B. J., Duncan, F. J., Meadows, A. S., Ware, T. A., Campbell, K., Bremer, W. G., Walker, C., Goodchild, L., Bolon, B., Perle, K. L., Flanigan, K., McBride, K. L., McCarty, D. M., & Fu, H. (2014). Feasibility and Safety of Systemic rAAV9-hNAGLU Delivery for Treating MPS IIIB: Toxicology, Bio-distribution and Immunological Assessments in Primates. Human Gene Therapy Clinical Development. https://doi.org/10.1089/hum.2013.208
Vancouver
Murrey DA, Naughton BJ, Duncan FJ, Meadows AS, Ware TA, Campbell K, et al. Feasibility and Safety of Systemic rAAV9-hNAGLU Delivery for Treating MPS IIIB: Toxicology, Bio-distribution and Immunological Assessments in Primates. Human Gene Therapy Clinical Development. 2014. doi:10.1089/hum.2013.208
BibTeX
@article{Murrey2014,
author = {Murrey, Darren A and Naughton, Bartholomew J and Duncan, F Jason and Meadows, Aaron S and Ware, Tierra Amber and Campbell, Katie and Bremer, William G and Walker, Christopher and Goodchild, Laurie and Bolon, Brad and Perle, Krista La and Flanigan, Kevin and McBride, Kim L and McCarty, Douglas M and Fu, Haiyan},
title = {Feasibility and Safety of Systemic rAAV9-hNAGLU Delivery for Treating MPS IIIB: Toxicology, Bio-distribution and Immunological Assessments in Primates},
journal = {Human Gene Therapy Clinical Development},
year = {2014},
doi = {10.1089/hum.2013.208}
}
EUVIMED